Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Neupogen biosimilar hits regulatory snag

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA issued Teva Pharmaceuticals a "complete response" on the BLA for Neutroval, its biosimilar formulation of Amgen's granulocyte colony-stimulating factor Neupogen for chemotherapy-induced neutropenia. Teva announced Sept. 30 that the agency had asked for "several items" but not for additional pre-market clinical trials, demonstrating that as pharmas explore regulatory pathways for biosimilars, going the full BLA route to approval will not guarantee a smooth review (1"Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble," "The Pink Sheet" DAILY, Oct. 1, 2010). The action letter was not entirely unexpected, given that both Teva and FDA are finding their way in the U.S. biosimilar space. FDA has scheduled a public hearing for Nov. 2-3 to gather input on implementing the legislation that enabled an approval pathway for generic biologics in this country. Meanwhile, Teva said it will work with the agency to find a pathway to approval, which could serve more than one objective. The Israeli biopharma is also working on a biosimilar of Amgen's Neupogen follow-on Neulasta (pegfilgrastim). Neutroval is already marketed in Europe as TevaGrastim. The European approval, however, doesn't seem to have made a big dent in Amgen's market share for the veteran product. According to Robert W. Baird analyst Raymond Christopher, Amgen's ex-U.S. market share is only off about 4% due to biosimilars, and its U.S. share "could prove similarly resilient," particularly because Amgen "fully intends to defend this franchise" through patent litigation

You may also be interested in...

Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble

FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.

QUOTED. 25 January. 2021. Scott Whitaker.

US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts